Dr. Atkins Discusses Response to Atezolizumab in RCC

Michael B. Atkins, MD
Published: Tuesday, Aug 15, 2017



Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma (RCC).

Data presented by David McDermott, MD, showed that there was a relationship between tumor microenvironment factors and efficacy with atezolizumab in RCC.

In the tumors that were T-effector high and myeloid low, atezolizumab alone or with bevacizumab (Avastin) showed better efficacy compared with sunitinib (Sutent). Conversely, in the T-effector high, myeloid-high subset, atezolizumab monotherapy did poorly, but did well with the addition of bevacizumab. This suggests that bevacizumab enhances the immune responsiveness of atezolizumab, says Atkins.
 


Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma (RCC).

Data presented by David McDermott, MD, showed that there was a relationship between tumor microenvironment factors and efficacy with atezolizumab in RCC.

In the tumors that were T-effector high and myeloid low, atezolizumab alone or with bevacizumab (Avastin) showed better efficacy compared with sunitinib (Sutent). Conversely, in the T-effector high, myeloid-high subset, atezolizumab monotherapy did poorly, but did well with the addition of bevacizumab. This suggests that bevacizumab enhances the immune responsiveness of atezolizumab, says Atkins.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x